Wondering which ASX shares could be buys?
Well, to narrow things down, let's see what experts are tipping as buys this week, courtesy of The Bull.
Here's what they are recommending:
Image source: Getty Images
Electro Optic Systems Holdings Ltd (ASX: EOS)
The team at MPC Markets is bullish on this defence and space company and has named it as a buy.
MPC Markets has been pleased with EOS' performance this year and believes recent share price weakness has created a buying opportunity for investors. It said:
This counter drone and laser weapons group had an order book of $846 million at June 30, 2026, an 84 per cent increase since December 31, 2025. In May, it completed the acquisition of the MARSS Group, a provider of artificial intelligence enabled command and control systems for counter drone capability.
The company upgraded full year 2026 revenue guidance to between $280 million and $300 million, excluding MARSS. The stock has fallen significantly between June 2 and July 30 to the point it has been materially over-sold, in our view. Investors can consider buying EOS on weakness.
Macquarie Group Ltd (ASX: MQG)
Over at Catapult Wealth, its analysts have named investment bank Macquarie as a buy this week.
The wealth management company believes Macquarie shares are a good alternative to the big four banks in the current environment. It explains:
Growth potential for the big four banks is likely to come under pressure from moderating house prices and investment loan demand. We see MQG as a compelling alternative in this environment due to Macquarie's more varied business mix.
Macquarie offers a global range of services that includes investment banking and asset management, which should enable it to offer solid growth even in a slowing retail banking environment. Macquarie's commodity and markets business can also benefit from market volatility, a useful trait in what is likely to be an uncertain period given the conflict in Iran.
Pro Medicus Ltd (ASX: PME)
MPC Markets is also bullish on Pro Medicus shares and has named them as a buy this week.
It thinks the market is undervaluing the health imaging technology company's growth, commenting:
The company provides medical imaging software and services to hospitals and health care groups across the world. It was removed from S&P/ASX 50 and the S&P Global 1200 in June, which left index funds dumping stock whether the business deserved it or not in terms of performance.
Reported half year net profit after tax of $171.2 million in the first half of 2026 was up 230.9 per cent on the prior corresponding period. The group keeps signing US hospital deals. Although the stock has bounced off its lows, we believe the market is still underpricing growth.
